

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

BUV395 Mouse Anti-Human CD56 Antibody

RRID:AB_2687886

Type: Antibody

Proper Citation

BD Biosciences Cat# 563554, RRID:AB_2687886

Antibody Information

URL: http://antibodyregistry.org/AB_2687886

Proper Citation: BD Biosciences Cat# 563554, RRID:AB_2687886

Target Antigen: CD56 (NCAM-1)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: BUV395 Mouse Anti-Human CD56 Antibody

Description: This monoclonal targets CD56 (NCAM-1)

Target Organism: human

Clone ID: NCAM16.2

Antibody ID: AB_2687886

Vendor: BD Biosciences

Catalog Number: 563554

Alternative Catalog Numbers: 563555

Record Creation Time: 20231110T034040+0000

Record Last Update: 20260829T031011+0000

Ratings and Alerts

No rating or validation information has been found for BUV395 Mouse Anti-Human CD56 Antibody.

No alerts have been found for BUV395 Mouse Anti-Human CD56 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

van Renterghem AWJ, et al. (2026) Liver metastases dampen IL18-driven ?? T cell activity and immunotherapy responsiveness in colorectal cancer. Cell reports. Medicine, 7(2), 102579.

Rollin P, et al. (2026) BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4+ Th1 responses. iScience, 29(2), 114676.

Mensching L, et al. (2025) HIV-1 infection of macrophages differentially primes NK-cell cytotoxicity and proinflammatory cytokine production. iScience, 28(7), 112879.

Cheung A, et al. (2024) Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(15), 3298.

Li Z, et al. (2024) Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors. STAR protocols, 5(3), 103096.

Li Z, et al. (2024) Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell, 187(3), 624.

Pulliam T, et al. (2024) Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma. Cell reports. Medicine, 5(2), 101412.

Sims EK, et al. (2023) Inhibition of polyamine biosynthesis preserves ? cell function in type 1 diabetes. Cell reports. Medicine, 4(11), 101261.

Grünhagel B, et al. (2023) Reduction of IFN-I responses by plasmacytoid dendritic cells in a longitudinal trans men cohort. iScience, 26(11), 108209.

Zonozi R, et al. (2023) T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19. Science translational medicine, 15(724), eadh4529.

Höfle J, et al. (2022) Engagement of TRAIL triggers degranulation and IFN? production in human natural killer cells. EMBO reports, 23(8), e54133.

Hagen SH, et al. (2021) Assessment of escape from X chromosome inactivation and gene expression in single human immune cells. STAR protocols, 2(3), 100641.

Wragg KM, et al. (2020) High CD26 and Low CD94 Expression Identifies an IL-23 Responsive V α 2⁺ T Cell Subset with a MAIT Cell-like Transcriptional Profile. Cell reports, 31(11), 107773.

Sharma A, et al. (2020) Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell, 183(2), 377.

Hagen SH, et al. (2020) Heterogeneous Escape from X Chromosome Inactivation Results in Sex Differences in Type I IFN Responses at the Single Human pDC Level. Cell reports, 33(10), 108485.

Körner C, et al. (2017) HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. Cell host & microbe, 22(1), 111.